Thoracic oncologists discuss HER2 testing, frontline treatment selection, and resistance mechanisms in HER2-altered non–small cell lung cancer.

The NMPA has accepted a supplemental application for subcutaneous toripalimab plus disitamab vedotin in first-line HER2-expressing urothelial carcinoma, following the May 2026 approval of the intravenous combination.

A Roswell Park–led phase 1/2 trial found bevacizumab plus pazopanib extended progression-free and overall survival in kidney cancer.

Breast cancer experts answer key questions on selecting, sequencing, and managing ADCs in HR-positive, HER2-positive, and triple-negative disease.

Prior immune checkpoint inhibitor exposure raised mucocutaneous adverse effect risk, particularly dermatitis, with lirafugratinib in FGFR2-altered tumors.

Trastuzumab deruxtecan plus pertuzumab improved systemic and intracranial outcomes in HER2-positive breast cancer with baseline brain metastases.

Petosemtamab plus pembrolizumab cut the risk of death by 50% in first-line PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma.

Relacorilant plus nab-paclitaxel and bevacizumab produced a 59% response rate in platinum-resistant ovarian cancer in Part A of the BELLA trial.